

**HBV Forum 2**  
**Tuesday, April 18, 2017**  
**Amsterdam, The Netherlands**  
**8:30 am - 12:30 pm**

**AGENDA**

7:30	<b>Breakfast and Registration</b>	
8:30	Welcome & Introductory Remarks	Veronica Miller, Forum for Collaborative Research William Symonds, Arbutus Biopharma Carol Brosgart, University of California San Francisco Nathaniel Brown, Hepatitis B Foundation
8:45	HDV RNA and anti-HDag testing in Europe	<b>Presenter:</b> Neville-Emmanuel Gordien, Hôpitaux Universitaires de Paris-Saint-Denis
9:05	Discussion	<b>All</b>
9:15	Detection, Assessment and Management of DILI During Drug Development for HBV: The IQ DILI Initiative	<b>Presenter:</b> Arie Regev, Eli Lilly & Company
9:35	Discussion	<b>All</b>
9:45	Mapping and modulation	<b>Presenter:</b> Stephen Locarnini, Victorian Infectious Diseases Reference Laboratory
10:05	Discussion	<b>All</b>
10:15	<b>Break</b>	
10:45	Working Group Updates: Diagnostics & Biomarkers	<b>Presenter:</b> Ed Marins, Roche Molecular Systems
11:00	Discussion	<b>All</b>
11:10	Working Group Updates: Treatment Combination	<b>Presenter:</b> Bruce Given, Arrowhead Research
11:25	Discussion	<b>All</b>
11:35	Working Group Updates: Surrogate Endpoints	<b>Presenter:</b> Oliver Lenz, Janssen Pharmaceuticals ID&V
11:50	Discussion	<b>All</b>
12:00	General discussion	<b>All</b>
12:30	<b>Adjourn &amp; Lunch</b>	

*\*This is not an official function/event of the European Association for the Study of the Liver (EASL) International Liver Congress™ 2017*